TriSalus Life Sciences To Become Publicly Traded Through Merger With MedTech Acquisition Corporation

11/14/22 7:24:38 AM ET

Medical Specialities

Health Care

Get the next $MTAC alert in real time by email

Oncology Therapeutics Company Focused on Transforming Cancer Treatment with Proprietary Innovative Therapies and Disruptive Delivery Technology

Company Has a Differentiated and Fast-growing, Commercial Drug Delivery Business; Significant Potential Upside from Immunotherapy Platform

Post-transaction, Expects to be Fully Funded to Allow Key Data Read-Outs for Device and Immunotherapy Platform in Late 2024

Accelerates Access to Resources to Drive Continued Commercialization of TriNav® Infusion System and Advance SD-101 Clinical Programs

Expected Cash at Closing Includes Up to $50 Million from an Anticipated Convertible Note from Leading Institutional Investor

Get the next $MTAC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MTAC

Date	Price Target	Rating	Analyst

More analyst ratings

$MTAC
Press Releases

Fastest customizable press release news feed in the world

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
Advances TriSalus' Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and Sales Growth Advancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Cholangiocarcinoma Provides Cash Runway through Mid-2024 to Fund Key Milestones TriSalus' Common Stock Expected to Begin Trading on the Nasdaq under Symbol "TLSI" on August 11, 2023 TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tu
8/10/23 4:05:00 PM ET
$MTAC
Medical Specialities
Health Care
MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders
MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or the "Company") today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the "Special Meeting"). The Special Meeting is being held to vote on certain proposals related to the proposed business combination (the "Business Combination") with TriSalus Life Sciences ("TriSalus"). The Special Meeting has been adjourned until 11:00 a.m. Eastern Time on August 8, 2023. The Special Meeting will still be held virtually via webcast, and stockholders may attend and participate online by visiting https://www.cstproxy.com/medtechacquisition/sm2023. Participants will be able to li
8/2/23 5:00:00 PM ET
$MTAC
Medical Specialities
Health Care
TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting
New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment and decreased circulating tumor DNA (ctDNA) levels TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company in the process of going public through a business combination transaction (the Business Combination) with MedTech Acquisition Corporation (NASDAQ:MTAC) (MedTech or MTAC), today announced additional Phase 1 clinical data presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting taking place in Chicago, Illinois, from June 2-6, 2023. TriSalus' ongoing Phase 1 Pressure-Enabled Regional Immuno-Oncology (PERIO-01) (NCT04935229) cl
6/12/23 7:00:00 AM ET
$MTAC
Medical Specialities
Health Care

TriSalus Life Sciences To Become Publicly Traded Through Merger With MedTech Acquisition Corporation

Chat with this insight

Recent Analyst Ratings for
$MTAC

$MTAC
Press Releases

Fastest customizable press release news feed in the world

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders

TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

$MTAC
SEC Filings

SEC Form 424B3 filed by MedTech Acquisition Corporation

SEC Form 424B3 filed by MedTech Acquisition Corporation

MedTech Acquisition Corporation filed SEC Form 8-K: Leadership Update

$MTAC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Szela Mary T was granted 84,899 shares, increasing direct ownership by 30% to 364,862 units (SEC Form 4)

Marshak Richard was granted 14,752 shares, increasing direct ownership by 118% to 27,251 units (SEC Form 4)

Cox Bryan F. was granted 14,752 shares, increasing direct ownership by 21% to 86,696 units (SEC Form 4)

$MTAC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by MedTech Acquisition Corporation

SEC Form SC 13G filed by MedTech Acquisition Corporation

SEC Form SC 13G filed by MedTech Acquisition Corporation

$MTAC
Leadership Updates

Live Leadership Updates

$MTAC
Market Insights

Live Market Insights

TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

TriSalus Life Sciences Completes Merger With MedTech Acquisition Corporation

MedTech Acquisition Corp Shares Resume Trade

MedTech Acquisition Corp Shares Halted On Circuit Breaker To The Upside, Stock Now Up 22.4%

TriSalus Life Sciences To Become Publicly Traded Through Merger With MedTech Acquisition Corporation

Chat with this insight

Recent Analyst Ratings for $MTAC

$MTAC Press Releases

Fastest customizable press release news feed in the world

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders

TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

$MTAC SEC Filings

SEC Form 424B3 filed by MedTech Acquisition Corporation

SEC Form 424B3 filed by MedTech Acquisition Corporation

MedTech Acquisition Corporation filed SEC Form 8-K: Leadership Update

$MTAC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Szela Mary T was granted 84,899 shares, increasing direct ownership by 30% to 364,862 units (SEC Form 4)

Marshak Richard was granted 14,752 shares, increasing direct ownership by 118% to 27,251 units (SEC Form 4)

Cox Bryan F. was granted 14,752 shares, increasing direct ownership by 21% to 86,696 units (SEC Form 4)

$MTAC Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by MedTech Acquisition Corporation

SEC Form SC 13G filed by MedTech Acquisition Corporation

SEC Form SC 13G filed by MedTech Acquisition Corporation

$MTAC Leadership Updates

Live Leadership Updates

$MTAC Market Insights

Live Market Insights

TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

TriSalus Life Sciences Completes Merger With MedTech Acquisition Corporation

MedTech Acquisition Corp Shares Resume Trade

MedTech Acquisition Corp Shares Halted On Circuit Breaker To The Upside, Stock Now Up 22.4%

Recent Analyst Ratings for
$MTAC

$MTAC
Press Releases

$MTAC
SEC Filings

$MTAC
Insider Trading

$MTAC
Large Ownership Changes

$MTAC
Leadership Updates

$MTAC
Market Insights